← All trials
NCT03043820
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2016
- Primary completion
- Dec 1, 2018
- Completion date
- Apr 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 154
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- UMC UtrechtLead sponsor
- Utrecht UniversityCollaborator
- Utrecht UniversityOverall official - principal investigator
- Utrecht UniversitySponsor investigator
- ZNA AntwerpenCollaborator
- AltrechtCollaborator
- Reinier van Arkel GroupCollaborator
- Geestelijke gezondheidszorg voor mensen in Eindhoven en omgevingCollaborator
- University of AmsterdamCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.